Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JW2286 in Healthy Volunteers
NCT06703710Phase 1Recruiting
- Sponsor
- JW Pharmaceutical Corporation
- Start
- Jan 2025
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in triple-negative breast cancer (TNBC), gastric cancer (GC) and colorectal cancer (CRC) comparing JW2286 with Placebo (2 arms). Primary endpoints: Area under the plasma drug concentration-time curve from 0 to last, Area under the plasma drug concentration-time curve from 0 to infinity and 2 more. Started Jan 2025; status: recruiting.
02
Drugs
JW2286
03
Conditions
triple-negative breast cancer (TNBC)gastric cancer (GC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06703710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06703710.